Tag Archives: Could

AMAG wins FDA nod for Vyleesi. Could it be the ‘female Viagra’ that Addyi never was?

Valeant, now Bausch Health, paid $ 1 billon in 2015 for Sprout Pharmaceuticals’ female libido drug Addyi, only to sell it back in 2017. Now as the drug is still nowhere near the blockbuster status Valeant once touted, a rival has arrived. The FDA late Friday approved AMAG Pharmaceuticals’ Vyleesi (bremelanotide) to treat premenopausal women with… Read More »

Patients’ own cells could be the key to treating Crohn’s disease

Rachel Sawyer, a communications manager who is 50 and lives in Anerley in south east London, was diagnosed with Crohn’s disease in 2000 and treated at Guy’s and St Thomas’. Although her condition is now under control, she supports other people who have Crohn’s and runs the Twitter account @Bottomline_IBD. She said: “One of the worst… Read More »